AZN

Equity

AstraZeneca PLC

Health Care · Drug Manufacturers - General

$208.45

+208.45 (+0.00%)

Open

N/A

Day Range

$206.95 - $209.93

52W Range

$122.26 - $212.71

Volume

2M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading

MT Newswires 8 hours ago

Analyst Report: Ionis Pharmaceuticals, Inc.

Morningstar Research 21 hours ago

AstraZeneca News On Cancer And Asthma Raises New Questions For Investors

Simply Wall St. 1 day ago

Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook

Zacks 1 day ago

AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff

Proactive 1 day ago

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
ABBV AbbVie Inc. $232.06 N/A 2.87% +0.00%
LLY Eli Lilly and Company $1,052.20 N/A 0.59% +0.00%
NVO Novo Nordisk A/S $37.46 N/A 4.49% +0.00%
EJG.F EBOS Group Ltd. R $11.70 N/A 5.14% +0.00%
5889.T JAPAN EYEWEAR HOLDINGS CO LTD $1,998.00 N/A 4.20% +0.00%
0332.KL TOPVISN $0.17 N/A 11.76% +0.00%
ABT Abbott Laboratories $116.32 N/A 2.06% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

www.astrazeneca.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Analysis Tools

Sign in for analysis tools

Share